• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用基于DNA的塞姆利基森林病毒载体进行快速、高水平的蛋白质生产。

Rapid, high level protein production using DNA-based Semliki Forest virus vectors.

作者信息

DiCiommo D P, Bremner R

机构信息

Eye Research Institute of Canada, Toronto, Ontario M5T 2S8.

出版信息

J Biol Chem. 1998 Jul 17;273(29):18060-6. doi: 10.1074/jbc.273.29.18060.

DOI:10.1074/jbc.273.29.18060
PMID:9660762
Abstract

Semliki Forest virus (SFV) vectors can be produced faster, and have a wider host range, than baculovirus vectors. However, the original SFV system requires in vitro manipulation of RNA. We have generated a system that is wholly DNA-based. Both the replicon vector, encoding SFV polymerase and the protein of interest, and the helper vector, encoding viral structural proteins, were modified so that expression was RNA polymerase II-dependent. Transfection of the modified replicon plasmid alone generated 20-30-fold more protein than obtained from a simple expression vector. Expression required the SFV replicase, which amplifies replicon RNA. The SFV-based vector generated 10-20-fold more protein than a plasmid based on Sindbis virus. Cotransfection of SFV replicon and helper vectors generated viral titers of around 10(6) infectious particles/ml. A single electroporation, plated on one 10-cm plate, generated enough virus (10(7) particles) to produce >500 microg of protein. Wild type, replication proficient virus was not detected in three tests utilizing almost 10(8) viral particles, a distinct advantage over a DNA Sindbis-based system in which over half the virus particles generated are fully infectious. The new SFV vectors significantly enhance the utility of this expression system.

摘要

辛德毕斯病毒(SFV)载体的制备速度比杆状病毒载体更快,宿主范围也更广。然而,最初的SFV系统需要对RNA进行体外操作。我们构建了一个完全基于DNA的系统。编码SFV聚合酶和目的蛋白的复制子载体以及编码病毒结构蛋白的辅助载体都经过了修饰,使其表达依赖于RNA聚合酶II。单独转染修饰后的复制子质粒所产生的蛋白比简单表达载体多20至30倍。表达需要SFV复制酶,它能扩增复制子RNA。基于SFV的载体产生的蛋白比基于辛德毕斯病毒的质粒多10至20倍。共转染SFV复制子和辅助载体可产生约10⁶个感染性颗粒/毫升的病毒滴度。单次电穿孔,接种在一个10厘米的培养皿上,产生的病毒量(10⁷个颗粒)足以产生超过500微克的蛋白。在使用近10⁸个病毒颗粒的三次测试中均未检测到野生型、具有复制能力的病毒,这相对于基于DNA的辛德毕斯病毒系统具有明显优势,在该系统中,超过一半产生的病毒颗粒具有完全感染性。新的SFV载体显著提高了该表达系统的实用性。

相似文献

1
Rapid, high level protein production using DNA-based Semliki Forest virus vectors.使用基于DNA的塞姆利基森林病毒载体进行快速、高水平的蛋白质生产。
J Biol Chem. 1998 Jul 17;273(29):18060-6. doi: 10.1074/jbc.273.29.18060.
2
[Construction of DNA and RNA based on bifunctional replicon vector derived from Semliki Forest virus].[基于源自塞姆利基森林病毒的双功能复制子载体构建DNA和RNA]
Sheng Wu Gong Cheng Xue Bao. 2005 Sep;21(5):713-8.
3
Semliki Forest virus and Sindbis virus vectors.塞姆利基森林病毒和辛德毕斯病毒载体。
Curr Protoc Hum Genet. 2002 Aug;Chapter 12:Unit 12.2. doi: 10.1002/0471142905.hg1202s33.
4
A novel three-plasmid packaging system for chimeric SFV/SIN VRPs derived from Semliki Forest virus and Sindbis virus as a candidate gene delivery vector.一种新型三质粒包装系统,用于源自 Semliki Forest 病毒和 Sindbis 病毒的嵌合 SFV/SIN VRPs,作为候选基因传递载体。
J Med Virol. 2024 Jan;96(1):e29376. doi: 10.1002/jmv.29376.
5
Efficient gene delivery into mammalian cells by recombinant baculovirus containing a hybrid cytomegalovirus promoter/Semliki Forest virus replicon.通过含有杂交巨细胞病毒启动子/辛德毕斯病毒复制子的重组杆状病毒高效转染哺乳动物细胞。
J Gene Med. 2009 Nov;11(11):1030-8. doi: 10.1002/jgm.1390.
6
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.
Biotechnology (N Y). 1991 Dec;9(12):1356-61. doi: 10.1038/nbt1291-1356.
7
Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors.水泡性口炎病毒糖蛋白:一种用于基于辛德毕斯病毒的RNA载体的转导衣壳
J Gene Med. 2004 Sep;6(9):1014-22. doi: 10.1002/jgm.582.
8
Generation of recombinant alphaviral vectors.重组甲病毒载体的产生。
Cold Spring Harb Protoc. 2012 Jul 1;2012(7):825-31. doi: 10.1101/pdb.prot070151.
9
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.用于辛德毕斯病毒和Semliki森林病毒衍生载体的稳定甲病毒包装细胞系。
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4598-603. doi: 10.1073/pnas.96.8.4598.
10
Expression of proteins using Semliki Forest virus vectors.使用辛德毕斯病毒载体表达蛋白质。
Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.20. doi: 10.1002/0471142727.mb1620s29.

引用本文的文献

1
Viral Vector-Based Cancer Vaccines.基于病毒载体的癌症疫苗
Methods Mol Biol. 2025;2926:101-127. doi: 10.1007/978-1-0716-4542-0_9.
2
Zinc-finger PARP proteins ADP-ribosylate alphaviral proteins and are required for interferon-γ-mediated antiviral immunity.锌指聚(ADP-核糖)聚合酶蛋白对甲病毒蛋白进行ADP核糖基化修饰,是γ干扰素介导的抗病毒免疫所必需的。
Sci Adv. 2025 Jan 31;11(5):eadm6812. doi: 10.1126/sciadv.adm6812.
3
Self-Replicating Alphaviruses: From Pathogens to Therapeutic Agents.自我复制的甲病毒:从病原体到治疗剂
Viruses. 2024 Nov 12;16(11):1762. doi: 10.3390/v16111762.
4
Application of DNA Replicons in Gene Therapy and Vaccine Development.DNA复制子在基因治疗和疫苗开发中的应用。
Pharmaceutics. 2023 Mar 15;15(3):947. doi: 10.3390/pharmaceutics15030947.
5
Alphaviruses in Immunotherapy and Anticancer Therapy.用于免疫治疗和抗癌治疗的甲病毒
Biomedicines. 2022 Sep 13;10(9):2263. doi: 10.3390/biomedicines10092263.
6
Alphaviruses in Cancer Therapy.用于癌症治疗的甲病毒
Front Mol Biosci. 2022 Apr 14;9:864781. doi: 10.3389/fmolb.2022.864781. eCollection 2022.
7
Facile method for delivering chikungunya viral replicons into mosquitoes and mammalian cells.将基孔肯雅病毒复制子递送至蚊子和哺乳动物细胞的简易方法。
Sci Rep. 2021 Jun 10;11(1):12321. doi: 10.1038/s41598-021-91830-y.
8
Self-Amplifying RNA Viruses as RNA Vaccines.自扩增 RNA 病毒作为 RNA 疫苗。
Int J Mol Sci. 2020 Jul 20;21(14):5130. doi: 10.3390/ijms21145130.
9
RNA-binding protein isoforms ZAP-S and ZAP-L have distinct antiviral and immune resolution functions.RNA 结合蛋白异构体 ZAP-S 和 ZAP-L 具有不同的抗病毒和免疫缓解功能。
Nat Immunol. 2019 Dec;20(12):1610-1620. doi: 10.1038/s41590-019-0527-6. Epub 2019 Nov 18.
10
Plasmid DNA-based Alphavirus Vaccines.基于质粒DNA的甲病毒疫苗。
Vaccines (Basel). 2019 Mar 8;7(1):29. doi: 10.3390/vaccines7010029.